Orforglipron vs. Tirzepatid
Maximale Wirkung oder maximaler Komfort? (2026)
Orforglipron vs. Tirzepatid Vergleich — Eli Lillys orale GLP-1-Pille gegen die duale GLP-1/GIP-Wocheninjektion.
Vergleich der Giganten
- ✓Einfache tägliche Tablette
- ✓Sehr gute Wirksamkeit für eine Pille
- ✓Keine Kühlung erforderlich
- ✓Aktuell stärkstes Mittel am Markt (~21%)
- ✓Dualer Wirkmechanismus (GLP-1 + GIP)
- ✓Nur 1x wöchentlich spritzen
Detailed Comparison
| Feature | Orforglipron | Tirzepatide |
|---|---|---|
| Mechanism | Oral non-peptide GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonistBest |
| Dosing | 12-36-45 mg orally daily (phase 2 doses) | 2.5-15 mg SC weekly |
| Administration | Oral | Subcutaneous injection weekly |
| Half-life | ~28-47 hours | ~5 days |
| FDA Status | Not FDA-approved — phase 3 clinical trials | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Wharton S et al. NEJM 2023 — phase 2 obesity trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | Nausea, vomiting, diarrhea (dose-dependent) | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
Orforglipron (oral non-peptide glp-1 receptor agonist) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Oral GLP-1 agonist space. Orforglipron small molecule oral glp-1 receptor agonist that does not require fasting for absorption — unlike oral semaglutide. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Orforglipron and Tirzepatide
Choosing between Orforglipron and Tirzepatide depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Orforglipron and Tirzepatide is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Orforglipron vs Tirzepatide: Häufig gestellte Fragen
Bisherige Daten deuten darauf hin, dass die Injektion von Tirzepatid einen etwas höheren Gewichtsverlust ermöglicht, aber Orforglipron für eine Pille extrem nah herankommt.
Orforglipron oder Tirzepatide in Shotlee tracken
Kostenloses Dosis-Tracking, Protokollierung von Nebenwirkungen und Ergebnisvergleich für jedes Medikationsprotokoll.